An observational study of alemtuzumab following fingolimod for multiple sclerosis

OBJECTIVE: To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS: Patients with relapsing MS treated sequentially with fingolimod then alem...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Mark, Pearson, Owen, Illes, Zsolt, Sejbaek, Tobias, Nielsen, Christian, Duddy, Martin, Petheram, Kate, van Munster, Caspar, Killestein, Joep, Malmeström, Clas, Tallantyre, Emma, Robertson, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226279/
https://www.ncbi.nlm.nih.gov/pubmed/28101520
http://dx.doi.org/10.1212/NXI.0000000000000320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226279/
https://www.ncbi.nlm.nih.gov/pubmed/28101520
http://dx.doi.org/10.1212/NXI.0000000000000320

Ejemplares similares